Home » Topics » BioWorld Science

BioWorld Science
RSS

CytomX Therapeutics describes auristatin-related compounds

Aug. 4, 2021

First patient dosed in a phase I study of ARX-517

Aug. 4, 2021

Antibe places its AME study of otenaproxesul on required pause

Aug. 4, 2021

LSD1 as potential therapeutic target in heart failure

Aug. 4, 2021

Cyclin C controls responses to PARP inhibitor treatment in BRCA2-deficient cells

Aug. 4, 2021

Luye Pharma files IND in U.S. to study next-generation VMAT2 inhibitor LY-03015

Aug. 3, 2021

FDA authorizes IND for phase I testing of Sorrento's CD38 DAR-T cell therapy candidate

Aug. 3, 2021

ACD-856 shows preclinical effects on cognition, enters phase I study

Aug. 3, 2021

Annovis reports interim phase II data on Posiphen in Alzheimer's and Parkinson's disease

Aug. 3, 2021

Dosing underway in phase I/II study of KRAS G12C inhibitor JAB-21822

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...